Abstract
Epirubicin, a stereoisomer of doxorubicin with suggested lower potential for cardiotoxicity in experimental animal tumor systems, was studied in a disease-oriented phase II trial in patients with advanced colorectal cancer. The drug was given as a direct iv injection of 90 mg/m2 q 3 weeks. No objective response was observed in 52 evaluable patients with colon (n = 34) and rectal (n = 18) carcinoma. Fourteen patients (27%) had stable disease for a median of four treatment courses. Leukopenia (88%), nausea and vomiting (71%) and alopecia (54%) were the most common toxic effects. We conclude that epirubicin at the present dose and schedule is an ineffective agent in patients with metastatic colorectal cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 63-66 |
Number of pages | 4 |
Journal | Investigational New Drugs |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - Mar 1985 |
Externally published | Yes |
Keywords
- colorectal cancer
- epirubicin
ASJC Scopus subject areas
- Pharmacology
- Molecular Medicine